Pharmacologic Substance
imatinib mesylate Audio
[ ih-ma-tih-nib meh-zih-layt ]
Effect:
Cellular Proliferation Alteration; Connective Tissue Alteration; Increased T Lymphocyte Destruction
May Treat:
Blast Crisis; Dermatofibrosarcoma; Gastrointestinal Neoplasms; Hypereosinophilic Syndrome; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Accelerated Phase; Mastocytosis, Systemic; Myelodysplastic-Myeloproliferative Diseases
More Information:
ChemID; DailyMed; DrugInfo; PDR
Definitions related to imatinib mesylate:
  • A drug used to treat different types of leukemia and other cancers of the blood, gastrointestinal stromal tumors, skin tumors called dermatofibrosarcoma protuberans, and a rare condition called systemic mastocytosis. It is also being studied in the treatment of other types of cancer. Imatinib mesylate blocks the protein made by the bcr/abl oncogene. It is a type of tyrosine kinase inhibitor.
    NCI Dictionary of Cancer Terms
    U.S. National Cancer Institute, 2021
  • A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.
    NLM Medical Subject Headings
    U.S. National Library of Medicine, 2021
  • The mesylate salt of imatinib, a tyrosine kinase inhibitor with antineoplastic activity. Imatinib binds to an intracellular pocket located within tyrosine kinases (TK), thereby inhibiting ATP binding and preventing phosphorylation and the subsequent activation of growth receptors and their downstream signal transduction pathways. This agent inhibits TK encoded by the bcr-abl oncogene as well as receptor TKs encoded by the c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Inhibition of the bcr-abl TK results in decreased proliferation and enhanced apoptosis in malignant cells of Philadelphia-positive (Ph+) hematological malignancies such as CML and ALL; effects on c-kit TK activity inhibit mast-cell and cellular proliferation in those diseases overexpressing c-kit, such as mastocytosis and gastrointestinal stromal tumor (GIST).
    NCI Thesaurus
    U.S. National Cancer Institute, 2021
Try this search on: Farlex, Merriam-Webster, Oxford Dictionary, or Wordnik

This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.